SCHEMBL12871

SCHEMBL12871

Cc1ccc(C(=O)N2CCOCC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PHGDH O43175 1/20 0.69
HPGD P15428 5/20 0.69
ALDH1A1 P00352 3/20 0.69
KDM4E B2RXH2 1/20 0.69
MAPT P10636 1/20 0.69
HTT P42858 1/20 0.69
SMN1; SMN2 Q16637 1/20 0.69
LMNA P02545 1/20 0.66
PKM P14618 1/20 0.65
MAPK1 P28482 2/20 0.62
AKR1C3 P42330 2/20 0.61
TSHR P16473 1/20 0.60
L3MBTL1 Q9Y468 2/20 0.59
RAB9A P51151 1/20 0.59
CYP1A2 P05177 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
POLB P06746 1/20 0.58
DNMT1 P26358 1/20 0.58
PTPN7 P35236 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17194215 0.95 HPGD (0.63) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL12947820 0.93 HPGD (0.61) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL10720943 0.90 PHGDH (0.81) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL25811334 0.89 ALDH1A1 (0.61) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL17888439 0.87 ALDH1A1 (0.69) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL10726712 0.86 ALDH1A1 (0.84) HPGDALDH1A1KDM4ELMNAPKM
SCHEMBL4557193 0.86 ALDH1A1 (0.84) HPGDALDH1A1KDM4ELMNAPKM
SCHEMBL12082793 0.85 ALDH1A1 (0.79) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL1017455 0.85 PHGDH (0.69) PHGDHHPGDALDH1A1KDM4EMAPT
SCHEMBL28296651 0.85 HPGD (0.86) PHGDHHPGDALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 331 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226318-A1 ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF Mabwell (shanghai) Bioscience Co., Ltd. (CN) 2024-07-11 US disclosed
US-20240226318-A1 ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF Mabwell (shanghai) Bioscience Co., Ltd. (CN) 2024-07-11 US disclosed
CN-111574477-B Synthesis method of amide compound 湖南大学 2024-06-28 CN disclosed
WO-2024072822-A2 DISPERSING AND WETTING AGENTS AND COMPOSITIONS AND METHODS OF USE THEREOF MOJAVE BIO, INC. (US) 2024-04-04 WO disclosed
WO-2024044486-A1 JAK2 INHIBITOR COMPOUNDS AJAX THERAPEUTICS, INC. (US) 2024-02-29 WO disclosed
US-11912708-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2024-02-27 US disclosed
US-11912708-B2 Macrocyclic heterocycles and uses thereof KUMQUAT BIOSCIENCES INC. (US) 2024-02-27 US disclosed
US-20230372526-A1 PREPARATION METHOD FOR BIS-SUBSTITUTED BRIDGING ANTIBODY-DRUG CONJUGATE Mabwell (shanghai) Bioscience Co., Ltd. (CN) 2023-11-23 US disclosed
US-20230372526-A1 PREPARATION METHOD FOR BIS-SUBSTITUTED BRIDGING ANTIBODY-DRUG CONJUGATE Mabwell (shanghai) Bioscience Co., Ltd. (CN) 2023-11-23 US disclosed
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF KUMQUAT BIOSCIENCES INC. 2023-10-26 US disclosed
WO-2007075468-A1 SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZONAPHTHYRIDINES, AND IMIDAZOPYRIDINES, COMPOSITIONS, AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-07-05 WO disclosed
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US disclosed
US-20070149560-A1 Novel fused triazolones and the uses thereof ASTRAZENECA AB (SE) 2007-06-28 US disclosed
WO-2007056341-A1 HETEROCYCLIC MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-18 WO disclosed
US-20070099901-A1 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-03 US disclosed
US-20070099901-A1 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines 3M INNOVATIVE PROPERTIES COMPANY (US) 2007-05-03 US disclosed
WO-2007039544-A1 NOVEL C18 MODIFIED RETROSTEROIDS AS PROGESTERONE RECEPTOR MODULATOR COMPOUNDS SOLVAY PHARMACEUTICALS GMBH (DE) 2007-04-12 WO disclosed
US-20070082876-A1 Novel C18 modified retrosteroids as progesterone receptor modulator compounds SOLVAY PHARMACEUTICALS GMBH (DE) 2007-04-12 US disclosed
EP-1757582-A1 ARYLALKYLAMINES AND PROCESS FOR PRODUCTION THEREOF TANABE SEIYAKU CO., LTD. (JP) 2007-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912708-B2 Macrocyclic heterocycles and uses thereof HRAS, KRAS, TP53 PHGDH 2010/4885HPGD 1824/4885ALDH1A1 4341/4885
US-20240226318-A1 ANTIBODY DRUG CONJUGATE TARGETING NECTIN 4 AND PREPARATION METHOD THEREFOR AND USE THEREOF NECTIN4, HAVCR2, CD4 PHGDH 4313/4885HPGD 4604/4885ALDH1A1 2721/4885
US-20070149560-A1 Novel fused triazolones and the uses thereof TP53, BRCA1, KLK3 PHGDH 3956/4885HPGD 1041/4885ALDH1A1 1270/4885
US-20070099901-A1 Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines IFNG, IRF3, IDO1 PHGDH 2163/4885HPGD 27/4885ALDH1A1 679/4885
US-20070082876-A1 Novel C18 modified retrosteroids as progesterone receptor modulator compounds HSD17B11, CYP19A1, CYP17A1 PHGDH 2357/4885HPGD 83/4885ALDH1A1 1289/4885
US-20070155739-A1 Substituted bis-amide metalloprotease inhibitors MMP13, MMP9, ADAMTS13 PHGDH 1275/4885HPGD 193/4885ALDH1A1 601/4885
US-20230372526-A1 PREPARATION METHOD FOR BIS-SUBSTITUTED BRIDGING ANTIBODY-DRUG CONJUGATE FHIT, BSG, FCGRT PHGDH 3542/4885HPGD 1746/4885ALDH1A1 465/4885
US-20230339952-A1 MACROCYCLIC HETEROCYCLES AND USES THEREOF HRAS, KRAS, TP53 PHGDH 2010/4885HPGD 1824/4885ALDH1A1 4341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.